Bristol-Myers Squibb (BMY) 8-K Bristol-myers Squibb Announces Second Quarter and Six Months Sales and Earnings for 2004

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
NET SALES
FOR THE PERIOD ENDED JUNE 30, 2004
($ in millions)

											Percentage Change
Quarter-to-Date	2004					2003					Including Foreign Exchange			Excluding Foreign Exchange
	Amount		% of Total			Amount		% of Total
Pharmaceuticals	$	3,831		70.6	%	$	3,631		70.8	%		6	%		2	%
US Pharmaceuticals		2,048		37.7	%		2,018		39.3	%		1	%		1	%
Primary Care		1,419		26.1	%		1,519		29.6	%		-7	%		-7	%
Oncology/Virology		510		9.4	%		435		8.5	%		17	%		17	%
Neuroscience		119		2.2	%		64		1.2	%		86	%		86	%
Latin America/Canada		257		4.7	%		240		4.7	%		7	%		4	%
Europe and Middle East Medicines		1,185		21.8	%		1,052		20.5	%		13	%		3	%
Asia/Pacific Medicines		293		5.4	%		256		5.0	%		14	%		6	%
Oncology Therapeutics Network		611		11.2	%		558		10.9	%		9	%		9	%
Nutritionals		510		9.4	%		521		10.2	%		-2	%		-2	%
Other Healthcare		478		8.8	%		419		8.1	%		14	%		10	%
ConvaTec		234		4.3	%		202		3.9	%		16	%		9	%
Medical Imaging		151		2.8	%		129		2.5	%		17	%		16	%
Consumer Medicines		93		1.7	%		88		1.7	%		6	%		4	%
Total Company	$	5,430		100.0	%	$	5,129		100.0	%		6	%		3	%

											Percentage Change
Year-to-Date	2004					2003					Including Foreign Exchange			Excluding Foreign Exchange
	Amount		% of Total			Amount		% of Total
Pharmaceuticals	$	7,522		70.9	%	$	6,996		71.0	%		8	%		3	%
US Pharmaceuticals		3,974		37.5	%		3,907		39.6	%		2	%		2	%
Primary Care		2,800		26.4	%		2,936		29.8	%		-5	%		-5	%
Oncology/Virology		942		8.9	%		870		8.8	%		8	%		8	%
Neuroscience		232		2.2	%		101		1.0	%		130	%		130	%
Latin America/Canada		508		4.8	%		454		4.6	%		12	%		7	%
Europe and Middle East Medicines		2,374		22.4	%		2,037		20.7	%		17	%		3	%
Asia/Pacific Medicines		561		5.3	%		482		4.9	%		16	%		6	%
Oncology Therapeutics Network		1,166		11.0	%		1,078		10.9	%		8	%		8	%
Nutritionals		1,012		9.5	%		979		9.9	%		3	%		3	%
Other Healthcare		911		8.6	%		804		8.2	%		13	%		8	%
ConvaTec		451		4.3	%		383		3.9	%		18	%		9	%
Medical Imaging		290		2.7	%		250		2.6	%		16	%		15	%
Consumer Medicines		170		1.6	%		171		1.7	%		-1	%		-4	%
Total Company	$	10,611		100.0	%	$	9,857		100.0	%		8	%		4	%

* Change is in excess of +/- 200%

BRISTOL-MYERS SQUIBB COMPANY
SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES
FOR THE PERIOD ENDED JUNE 30, 2004
(DOLLARS IN MILLIONS)

QUARTER-TO-DATE
				Oncology
				Therapeutics												Consumer
	Pharmaceuticals			Network			Nutritionals			Convatec			Medical Imaging			Medicines			Total Company
Price Increases(Decreases)		1	%		—			6	%		—			2	%		1	%		1	%
Foreign Exchange		4	%		—			—			7	%		1	%		2	%		3	%
Volume		1	%		9	%		-8	%		9	%		14	%		3	%		2	%
Total Change		6	%		9	%		-2	%		16	%		17	%		6	%		6	%
Total 2003 Period to Date Sales	$	3,831		$	611		$	510		$	234		$	151		$	93		$	5,430
Total 2002 Period to Date Sales	$	3,631		$	558		$	521		$	202		$	129		$	88		$	5,129

YEAR-TO-DATE
				Oncology
				Therapeutics												Consumer
	Pharmaceuticals			Network			Nutritionals			Convatec			Medical Imaging			Medicines			Total Company
Price Increases(Decreases)		-1	%		—			4	%		—			4	%		—			—
Foreign Exchange		5	%		—			—			9	%		1	%		3	%		4	%
Volume		4	%		8	%		-1	%		9	%		11	%		-4	%		4	%
Total Change		8	%		8	%		3	%		18	%		16	%		-1	%		8	%
Total 2004 Period to Date Sales	$	7,522		$	1,166		$	1,012		$	451		$	290		$	170		$	10,611
Total 2003 Period to Date Sales	$	6,996		$	1,078		$	979		$	383		$	250		$	171		$	9,857

BRISTOL-MYERS SQUIBB COMPANY
2004 SECOND QUARTER REVIEW
($ in Millions)

Corporate Overview

Revenues:	2004			% of Total			2003			% of Total			%Var.
Pharmaceuticals	$	3,831			70.6	%	$	3,631			70.8	%		6	%
Oncology Therapeutics Network		611			11.2	%		558			10.9	%		9	%
Nutritionals		510			9.4	%		521			10.2	%		-2	%
Other Healthcare		478			8.8	%		419			8.1	%		14	%
ConvaTec		234			4.3	%		202			3.9	%		16	%
Medical Imaging		151			2.8	%		129			2.5	%		17	%
Consumer Medicines		93			1.7	%		88			1.7	%		6	%
		5,430			100.0	%		5,129			100.0	%		6	%
Expenses:				% of Sales						% of Sales			%Var.
COGS		2,095			38.6	%		1,852			36.1	%		13	%
SG&A		1,212			22.3	%		1,147			22.4	%		6	%
Adv. & Promo.		346			6.4	%		354			6.9	%		-2	%
R&D		625			11.5	%		524			10.2	%		19	%
In-process R&D		62			1.1	%		—			—			—
Gain on sale of businesses		(18	)		-0.3	%		—			—			—
Provision for restructuring		6			0.1	%		(7	)		-0.1	%		186	%
Litigation settlement expense/(income)		379			7.0	%		(41	)		-0.9	%		*
Equity in net income of affiliates		(59	)		-1.1	%		(48	)		-0.9	%		-23	%
Other (Inc)/Exp		7			0.1	%		101			2.0	%		-93	%
		4,655			85.7	%		3,882			75.7	%		20	%
Earnings Before Minority Interest and Income Taxes		775			14.3	%		1,247			24.3	%		-38	%
Provision for income taxes		120						262
Minority interest, net of taxes		128						83
Net Earnings	$	527			9.7	%	$	902			17.6	%		-42	%
Earnings Per Share — Basic	$	0.27					$	0.47						-43	%
Average Shares — Basic		1,942						1,937
Earnings Per Share — Diluted	$	0.27					$	0.46						-41	%
Average Shares — Diluted		1,976						1,942

* in excess of +/- 200%

	Worldwide					Change in U.S.
	Sales					Rx Demand
Selected Products	$ in Millions		%Var.			3Q03 vs. 3Q02
Plavix	$	769		38	%		25	%
Pravachol/Pravigard Pac		656		-6	%		-9	%
Avapro/Avalide		233		37	%		15	%
Enfamil		224		-4	%		N/A
Sustiva		153		-4	%		5	%
Ostomy		137		9	%		N/A
Wound Therapeutics		94		29	%		N/A
Zerit		78		-20	%		-28	%
Coumadin		77		-18	%		-19	%
Videx/Videx EC		69		-1	%		-1	%
Glucovance		47		-59	%		-38	%
Glucophage XR		10		-90	%		-78	%

Other (Income)/Expense	2004			2003
Interest Expense		70			78
Interest Income		(22	)		(12	)
Foreign Exchange		38			6
Other — net		(79	)		29
		7			101

BRISTOL-MYERS SQUIBB COMPANY
2004 SIX MONTH REVIEW
($ in Millions)

Corporate Overview

Revenues:	2004			% of Total			2003			% of Total			%Var.
Pharmaceuticals	$	7,522			70.9	%	$	6,996			71.0	%		8	%
Oncology Therapeutics Network		1,166			11.0	%		1,078			10.9	%		8	%
Nutritionals		1,012			9.5	%		979			9.9	%		3	%
Other Healtcare		911			8.6	%		804			8.2	%		13	%
ConvaTec		451			4.3	%		383			3.9	%		18	%
Medical Imaging		290			2.7	%		250			2.6	%		16	%
Consumer Medicines		170			1.6	%		171			1.7	%		-1	%
		10,611			100.0	%		9,857			100.0	%		8	%
Expenses:				% of Sales						% of Sales			%Var.
COGS		3,994			37.6	%		3,561			36.1	%		12	%
SG&A		2,446			23.1	%		2,247			22.8	%		9	%
Adv. & Promo.		662			6.2	%		669			6.8	%		-1	%
R&D		1,208			11.4	%		999			10.1	%		21	%
In-process R&D		62			0.6	%		—			—			—
Gain on sale of businesses		(313	)		-2.9	%		—			—			—
Provision for restructuring and other items		18			0.2	%		5			0.1	%		*
Litigation settlement expense/(income)		379			3.6	%		(62	)		-0.6	%		*
Equity in net income of affiliates		(134	)		-1.3	%		(70	)		-0.7	%		-91	%
Other (Inc)/Exp, net		45			0.4	%		98			1.0	%		-54	%
		8,367			78.9	%		7,447			75.6	%		12	%
Earnings Before Minority Interest and Income Taxes		2,244			21.1	%		2,410			24.4	%		-7	%
Provision for income taxes		518						578
Minority interest, net of taxes		235						138
Net Earnings	$	1,491			14.1	%	$	1,694			17.2	%		-12	%
Earnings Per Share — Basic	$	0.77					$	0.88						-13	%
Average Shares — Basic		1,940						1,936
Earnings Per Share — Diluted	$	0.76					$	0.87						-13	%
Average Shares — Diluted		1,976						1,941

* in excess of +/- 200%

	Worldwide					Change in U.S.
	Sales					Rx Demand
Selected Products	$ in Millions		%Var.			YTD 04 vs. YTD 03
Plavix	$	1,466		52	%		28	%
Pravachol/Pravigard Pac		1,327		1	%		-5	%
Enfamil		432		9	%		N/A
Avapro/Avalide		430		25	%		16	%
Sustiva		292		-6	%		6	%
Ostomy		264		11	%		N/A
Wound Therapeutics		181		28	%		N/A
Glucovance		149		-33	%		-19	%
Videx/Videx EC		140		-1	%		-1	%
Zerit		136		-36	%		-29	%
Coumadin		114		-37	%		-18	%
Glucophage XR		29		-86	%		-74	%

Other (Income)/Expense	2004			2003
Interest Expense		139			159
Interest Income		(39	)		(32	)
Foreign Exchange		55			(34	)
Other — net		(110	)		5
		45			98

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE THREE MONTHS ENDED JUNE 30, 2004
($ in millions)

	WORLDWIDE									INTERNATIONAL *								DOMESTIC *
	2004			2003			% growth			2004			2003		% growth			2004			2003			% growth
Total Company	$	5,430		$	5,129			6	%	$	2,157		$	1,963		10	%	$	3,273		$	3,166			3	%
PHARMACEUTICALS		3,831			3,631			6	%		1,760			1,582		11	%		2,071			2,049			1	%
Cardiovasculars		1,891			1,708			11	%		684			606		13	%		1,207			1,102			10	%
Plavix		769			557			38	%		118			85		39	%		651			472			38	%
Pravachol/Pravigard Pac		656			698			-6	%		330			301		10	%		326			397			-18	%
Avapro/ Avalide		233			170			37	%		89			73		22	%		144			97			48	%
Monopril		72			109			-34	%		59			60		-2	%		13			49			-73	%
Capoten/Captopril		48			49			-2	%		48			49		-2	%		—			—			—
Coumadin		77			94			-18	%		7			7		—			70			87			-20	%
Anti-Cancer		619			561			10	%		329			302		9	%		290			259			12	%
TAXOL		249			248			—			248			223		11	%		1			25			-96	%
Paraplatin		241			247			-2	%		35			34		3	%		206			213			-3	%
Erbitux		72			—			—			—			—		—			72			—			—
Anti-Infectives		679			625			9	%		399			368		8	%		280			257			9	%
Sustiva		153			160			-4	%		63			55		15	%		90			105			-14	%
Reyataz		85			1			*	**		20			1		*	**		65			—			—
Cefzil		55			59			-7	%		26			21		24	%		29			38			-24	%
Videx/ Videx EC		69			70			-1	%		44			40		10	%		25			30			-17	%
Zerit		78			98			-20	%		40			48		-17	%		38			50			-24	%
Maxipime		50			45			11	%		50			45		11	%		—			—			—
Tequin		39			40			-3	%		13			9		44	%		26			31			-16	%
Central Nervous System		44			103			-57	%		44			42		5	%		—			61			-100	%
Sinemet		27			31			-13	%		22			21		5	%		5			10			-50	%
BuSpar		1			11			-91	%		6			7		-14	%		(5	)		4			*	**
Serzone		(3	)		41			-107	%		(1	)		1		-200	%		(2	)		40			*	**
Other Pharmaceuticals
Glucophage Franchise		79			240			-67	%		6			5		20	%		73			235			-69	%
Glucovance		47			116			-59	%		1			2		-50	%		46			114			-60	%
Glucophage		12			26			-54	%		3			2		50	%		9			24			-63	%
Glucophage XR		10			102			-90	%		1			1		—			9			101			-91	%
Metaglip		10			(4	)		*	**		1			—		—			9			(4	)		*	**
Abilify**		122			65			88	%		3			1		200	%		119			64			86	%
ONCOLOGY THERAPEUTICS NETWORK		611			558			9	%		—			—		—			611			558			9	%
NUTRITIONALS		510			521			-2	%		261			240		9	%		249			281			-11	%
Infant Formulas		365			345			6	%		126			114		11	%		239			231			3	%
Enfamil		224			233			-4	%		70			65		8	%		154			168			-8	%
Other Nutritional Products
Toddler/Children’s Nutritionals		118			103			15	%		118			103		15	%		—			—			—
Adult Consumer Nutritionals		9			37			-76	%		7			11		-36	%		2			26			-92	%
OTHER HEALTHCARE		478			419			14	%		214			191		12	%		264			228			16	%
CONVATEC PRODUCTS		234			202			16	%		163			140		16	%		71			62			15	%
Ostomy		137			126			9	%		96			88		9	%		41			38			8	%
Wound Therapeutics		94			73			29	%		64			50		28	%		30			23			30	%
MEDICAL IMAGING		151			129			17	%		24			17		41	%		127			112			13	%
Cardiolite		105			86			22	%		13			9		44	%		92			77			19	%
CONSUMER MEDICINES		93			88			6	%		27			34		-21	%		66			54			22	%

*	This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.
**	Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
***	In Excess of +/- 200%

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE SIX MONTHS ENDED JUNE 30, 2004
($ in millions)

	WORLDWIDE									INTERNATIONAL *								DOMESTIC *
	2004			2003			% growth			2004			2003		% growth			2004			2003			% growth
Total Company	$	10,611		$	9,857			8	%	$	4,275		$	3,761		14	%	$	6,336		$	6,096			4	%
PHARMACEUTICALS		7,522			6,996			8	%		3,485			3,033		15	%		4,037			3,963			2	%
Cardiovasculars		3,639			3,197			14	%		1,358			1,151		18	%		2,281			2,046			11	%
Plavix		1,466			965			52	%		230			158		46	%		1,236			807			53	%
Pravachol/Pravigard Pac		1,327			1,311			1	%		658			572		15	%		669			739			-9	%
Avapro/ Avalide		430			345			25	%		170			131		30	%		260			214			21	%
Monopril		137			232			-41	%		125			118		6	%		12			114			-89	%
Coumadin		114			182			-37	%		13			12		8	%		101			170			-41	%
Capoten/Captopril		94			98			-4	%		94			98		-4	%		—			—			—
Anti-Cancer		1,162			1,044			11	%		632			560		13	%		530			484			10	%
TAXOL		492			457			8	%		477			415		15	%		15			42			-64	%
Paraplatin		469			456			3	%		65			61		7	%		404			395			2	%
Erbitux		89			—			—			—			—		—			89			—			—
Anti-Infectives		1,328			1,325			—			783			717		9	%		545			608			-10	%
Sustiva		292			310			-6	%		126			101		25	%		166			209			-21	%
Reyataz		160			1			*	**		29			1		*	**		131			—			—
Videx/ Videx EC		140			142			-1	%		86			77		12	%		54			65			-17	%
Zerit		136			213			-36	%		82			96		-15	%		54			117			-54	%
Cefzil		127			172			-26	%		56			46		22	%		71			126			-44	%
Maxipime		94			87			8	%		94			87		8	%		—			—			—
Tequin		78			98			-20	%		24			17		41	%		54			81			-33	%
Central Nervous System		90			185			-51	%		84			82		2	%		6			103			-94	%
Sinemet		50			54			-7	%		43			40		8	%		7			14			-50	%
BuSpar		6			25			-76	%		13			15		-13	%		(7	)		10			-170	%
Serzone		(4	)		70			-106	%		(1	)		5		-120	%		(3	)		65			-105	%
Other Pharmaceuticals
Glucophage Franchise		240			487			-51	%		12			9		33	%		228			478			-52	%
Glucovance		149			224			-33	%		3			3		—			146			221			-34	%
Glucophage		43			63			-32	%		7			5		40	%		36			58			-38	%
Glucophage XR		29			203			-86	%		1			1		—			28			202			-86	%
Metaglip		19			(3	)		*	**		1			—		—			18			(3	)		*	**
Abilify**		237			102			132	%		5			1		*	**		232			101			130	%
ONCOLOGY THERAPEUTICS NETWORK		1,166			1,078			8	%		—			—		—			1,166			1,078			8	%
NUTRITIONALS		1,012			979			3	%		513			468		10	%		499			511			-2	%
Infant Formulas		704			619			14	%		247			215		15	%		457			404			13	%
Enfamil		432			398			9	%		136			120		13	%		296			278			6	%
Other Nutritional Products
Toddler/Children’s Nutritionals		232			204			14	%		232			204		14	%		—			—			—
Adult Consumer Nutritionals		31			70			-56	%		16			22		-27	%		15			48			-69	%
OTHER HEALTHCARE		911			804			13	%		402			356		13	%		509			448			14	%
CONVATEC PRODUCTS		451			383			18	%		309			258		20	%		142			125			14	%
Ostomy		264			237			11	%		183			162		13	%		81			75			8	%
Wound Therapeutics		181			141			28	%		121			93		30	%		60			48			25	%
MEDICAL IMAGING		290			250			16	%		43			36		19	%		247			214			15	%
Cardiolite		197			161			22	%		22			19		16	%		175			142			23	%
CONSUMER MEDICINES		170			171			-1	%		50			62		-19	%		120			109			10	%

*	This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.
**	Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
***	In Excess of +/- 200%

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES
EXCLUDING SPECIFIED ITEMS

	2003
	Q1			Q2			Q3			Q4		TOTAL YEAR
Earnings Before Minority Interest and Income Taxes	$	1,163		$	1,247		$	1,361		$	923	$	4,694
Specified items:
Provision for restructuring / other		26			4			55			110		195
Litigation (recoveries) / charges		(21	)		(41	)		(4	)		265		199
Earnings Before Minority Interest and Income Taxes
Excluding Specified Items	$	1,168		$	1,210		$	1,412		$	1,298	$	5,088

	2004
	Q1			Q2			TOTAL YEAR
Earnings Before Minority Interest and Income Taxes	$	1,469		$	775		$	2,244
Specified items:
Gain on sale of businesses		(295	)		(18	)		(313	)
In-process research and development		—			62			62
Provision for restructuring / other		34			42			76
Litigation reserves		—			455			455
Earnings Before Minority Interest and Income Taxes
Excluding Specified Items	$	1,208		$	1,316		$	2,524

BRISTOL-MYERS SQUIBB COMPANY
DILUTED EARNINGS PER COMMON SHARE
EXCLUDING SPECIFIED ITEMS

	2003
	Q1			Q2			Q3 *		Q4		TOTAL YEAR *
Diluted Earnings per Common Share	$	0.41		$	0.46		$	0.47	$	0.26	$	1.59
Specified items:
Provision for restructuring / other		0.01			—			0.02		0.04		0.07
Litigation (recoveries) / charges		(0.01	)		(0.01	)		—		0.13		0.11
Diluted Earnings per Common Share
Excluding Specified Items *	$	0.41		$	0.45		$	0.48	$	0.43	$	1.78

	2004
	Q1			Q2			TOTAL YEAR
Diluted Earnings per Common Share	$	0.49		$	0.27		$	0.76
Specified items:
Gain on sale of businesses		(0.09	)		(0.01	)		(0.10	)
In-process research and development		—			0.03			0.03
Provision for restructuring / other		0.01			0.02			0.03
Litigation reserves		—			0.15			0.15
Diluted Earnings per Common Share
Excluding Specified Items	$	0.41		$	0.46		$	0.87

* amounts may not add due to rounding of individual calculations.

BRISTOL-MYERS SQUIBB COMPANY
SELECT ADDITIONAL FINANCIAL INFORMATION

	($ in Millions)
	June 30,			December 31,
Balance Sheet Items	2004			2003
Cash, cash equivalents and marketable debt securities	$	6,844		$	5,457
Receivables, net of allowances		3,508			3,646
Short-term borrowings		1,009			127
Long-term debt		8,376			8,522
Stockholders’ equity	$	10,431		$	9,786
Other Items
For the three months ended June 30, 2004:
Quarterly Dividend	$.28/share
Gross Margin		61.4	%
Capital Expenditures and Capitalized Software	$185million

BRISTOL-MYERS SQUIBB COMPANY
2004 DILUTED EPS IMPACT OF PROJECTED SPECIFIED ITEMS

	Diluted EPS
	Impact
Litigation reserves	$	(0.15	)
Gain on sale of Adult Nutritional Business		0.10
Anticipated restructuring/relocation		(0.07	)
Preliminary estimate of charge for in-process research and development from acquisition of Acordis		(0.03	)
Licensing Milestones		(0.02	)
Total	$	(0.17	)